BPC-157 vs Follistatin-344
Updated July 27, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of BPC-157 and Follistatin-344 (also searched as Follistatin-344 vs BPC-157) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
BPC-157 centers on healing, while Follistatin-344 leans toward muscle. On indexed research, BPC-157 is ahead (BPC-157: 7 studies, Human evidence; Follistatin-344: 5, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •BPC-157 is strongest for healing; Follistatin-344 for muscle.
- •Evidence: BPC-157 Human evidence (7 studies) vs Follistatin-344 Human evidence (5).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
Body Protection Compound-157 | Pentadecapeptide
Myostatin inhibition | Muscle growth
BPC-157 vs Follistatin-344: side-by-side
| Metric | BPC-157 | Follistatin-344 |
|---|---|---|
| Class | Healing | Muscle |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human evidence | Human evidence |
| Studies indexed | 7 | 5 |
| Research level | Extensively Studied | Limited Research |
| Strongest effect | Healing & recovery | Muscle & body comp |
| Healing & recovery | 4.0▲ | 1.0 |
| Muscle & body comp | 3.0 | 5.0▲ |
| Metabolic & appetite | 2.0▲ | 2.0▲ |
| Neuro & mood | 3.0▲ | 1.0 |
| Sleep & circadian | 1.0▲ | 0.0 |
| Inflammation & immune | 4.0▲ | 1.0 |
| Skin & aesthetics | 2.0▲ | 2.0▲ |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | BPC-157 | Follistatin-344 |
|---|---|---|
| Mechanism | Body-protective compound (pentadecapeptide); cytoprotective, pro-angiogenic signaling | Myostatin inhibitor |
| Route | Subcutaneous / oral (research use) | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is BPC-157?
Body Protective Compound often discussed for soft-tissue repair, GI support, and inflammation modulation.
Full BPC-157 profile, mechanism & studies →What is Follistatin-344?
### Follistatin-344 Summary Follistatin-344 is a glycoprotein that plays a crucial role in the regulation of muscle growth and development by inhibiting myostatin, a negative regulator of muscle mass. Its potential therapeutic applications are being explored in various fields, including muscle wasting disorders and regenerative medicine.
Full Follistatin-344 profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | BPC-157 | 4.0/5 effect signal |
| Muscle | Follistatin-344 | 5.0/5 effect signal |
| Metabolic | Even | Both ~2.0/5 |
| Neuro | BPC-157 | 3.0/5 effect signal |
| Sleep | BPC-157 | 1.0/5 effect signal |
| Inflammation | BPC-157 | 4.0/5 effect signal |
| Skin | Even | Both ~2.0/5 |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack BPC-157 and Follistatin-344?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
BPC-157 vs Follistatin-344: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
BPC-157 has 7 approved studies indexed (Human evidence), and Follistatin-344 has 5 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is BPC-157 or Follistatin-344 better?
It depends on your goal. BPC-157 is strongest for healing; Follistatin-344 for muscle. BPC-157 has more indexed studies (7). See the goal-by-goal breakdown above.
Is BPC-157 or Follistatin-344 better for weight loss?
They score similarly on the metabolic/appetite axis in the community data.
Is BPC-157 or Follistatin-344 better for muscle?
Follistatin-344 leads on the muscle & body-composition axis (5.0/5).
Which has more research, BPC-157 or Follistatin-344?
BPC-157 has 7 approved studies indexed (Human evidence); Follistatin-344 has 5 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack BPC-157 and Follistatin-344?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of BPC-157 vs Follistatin-344?
BPC-157: no community-reported effects logged yet. Follistatin-344: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is BPC-157 or Follistatin-344 FDA-approved?
BPC-157 is a research-use compound and is not FDA-approved. Follistatin-344 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Follistatin-344 better than BPC-157?
For muscle, Follistatin-344 has the edge; for healing, BPC-157 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
BPC-157 and Follistatin-344 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 27, 2026.